CD38 and Miyoshi myopathy: Based on the pivotal KarMMa-1 and CARTITUDE-1 trials, these products were initially reserved for heavily pretreated MM patients who received at least 4 lines of therapy, including an immunomodulatory agent, proteasome inhibitor and an anti-CD38 monoclonal antibody.